AstraZeneca’s Dapagliflozin receives CDSCO approval with additional indication for treatment of patients with Chronic Kidney Disease and Heart Failure
AstraZeneca India announced that the company has received the Central Drugs Standard Control Organization’s (CDCSCO) approval for their anti-diabetic drug
Read More